MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neurofibrillary tangles(NFT)"

  • 2026 International Congress

    Senile Plaques and Neurofibrillary Tangles Modulate Lewy Body Distribution: Autopsy Study of 2,308 Cases

    H. Sekiya, D. Ono, D. Dickson (Jacksonville, USA)

    Objective: To understand how Lewy body (LB) pathology progresses in the cerebrum and how Alzheimer's disease (AD) pathology influences LB distribution in LB disease (LBD).…
  • 2025 International Congress

    Amygdala-predominant Lewy Body Disease is a Lens for Understanding Pathogenesis and the Alpha-synuclein Seeding Assay in Human Postmortem Brain

    D. Fischer, L. Vandevrede, W. Seeley, S. Spina, S. Li, W. Lee, T. Lamore, F. Wekselman, A. Lario Lago, L. Grinberg (San Francisco, USA)

    Objective: To map alpha-synuclein (asyn) and tau markers in amygdala-predominant Lewy body disease (AP-LBD), identifying spread pathways and vulnerable cell populations. Background: LBD often co-occurs…
  • MDS Virtual Congress 2020

    Sex Moderates the Effects of Neurofibrillary Tangles on Cognition for Diffuse Lewy Body Pathology

    E. Bayram, I. Litvan (La Jolla, CA, USA)

    Objective: To evaluate (1) the association between neurofibrillary tangle staging and cognition for participants with diffuse Lewy Body (LB) pathology, (2) whether this association differs…
  • MDS Virtual Congress 2020

    Diagnostic utility of cerebrospinal fluid t-tau/p-tau181 in Parkinson’s disease with mild cognitive impairment: A cross-sectional study in Chinese cohort

    P. Zhang, Y. Li, L.J Wang, Y.H Zhang (Guangzhou, China)

    Objective: This study explores the value of α-Syn, Aβ1-42, t-tau, p-tau181 in cerebrospinal fluid(CSF) and their ratios for the diagnosis of Parkinson's disease with mild…
  • MDS Virtual Congress 2020

    The ADNPC-RS: a risk score that identifies Lewy body disease individuals at risk for developing concomitant Alzheimer’s pathology

    D. Dai, T. Tropea, J. Robinson, E. Suh, H. Hurtig, D. Weintraub, V. Van Deerlin, E. Lee, J. Trojanowski, A. Chen-Plotkin (Philadelphia, PA, USA)

    Objective: To identify which common genetic variants that confer risk for Alzheimer’s disease (AD) also predict the development of concomitant AD pathology in patients with…
  • 2017 International Congress

    18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease

    A. Hansen, M. Damholdt, K. Knudsen, T. Fedorova, K. Østergaard, D. Brooks, P. Borghammer (Aarhus C, Denmark)

    Objective: To describe cortical and subcortical 18F-AV-1451 binding in Parkinson’s disease patients with and without mild cognitive impairment (PD-MCI and PD-nonMCI). Background: The radioligand 18F-AV-1451…
  • 2017 International Congress

    The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients

    I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, K. Brockmann, T. Gasser, S. Becker, J. Streffer, D. Berg (Tübingen, Germany)

    Objective: To define cerebrospinal fluid (CSF) levels of Amyloid-beta 1-42 (Aß1-42-), total (h-) and phosphorylated (p-)Tau in a large cohort of non-demented Parkinson’s disease (PD)…
  • 2016 International Congress

    Phosphorylation by GSK-3β enhances binding of metal ion induced tau oligomers to neutral lipid surfaces

    G.S. Nuebling, E. Plesch, T. Högen, S. Lorenzl, F. Kamp, A. Giese (Munich, Germany)

    Objective: To dissect the complex interplay of tau hyperphosphorylation, metal ion induced oligomer formation and membrane interactions applying single particle fluorescence techniques. Background: Fibrillar deposits…
  • 2016 International Congress

    Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report

    K. Giehl, K. Reetz, I. Dogan, C. Werner, J.B. Schulz, A. Drzezga, T. van Eimeren (Köln, Germany)

    Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…
  • 2016 International Congress

    In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET

    H. Endo, H. Shimada, Y. Kimura, M. Ichise, M. Ono, H. Shinotoh, F. Niwa, S. Kitamura, K. Takahata, S. Hirano, S. Koga, D.W. Dickson, N. Sahara, M. Yamada, M. Higuchi, T. Toda, T. Suhara (Chiba, Japan)

    Objective: This study was aimed at evaluating pathological tau accumulations in the brains of patients with progressive supranuclear palsy (PSP) and young and old healthy…

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley